Related references
Note: Only part of the references are listed.Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Alessandro Di Federico et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2022)
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
Vera Himmelsbach et al.
CANCERS (2022)
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Zhenwei Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
Robin Kate Kelley et al.
LANCET ONCOLOGY (2022)
Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
R. S. Finn et al.
ANNALS OF ONCOLOGY (2022)
Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
S. Qin et al.
ANNALS OF ONCOLOGY (2022)
Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
S. Qin et al.
ANNALS OF ONCOLOGY (2022)
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi et al.
EUROPEAN JOURNAL OF CANCER (2022)
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma
Giuseppe Cabibbo et al.
LANCET ONCOLOGY (2022)
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE CANCER (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Donafenib: First Approval
Susan J. Keam et al.
DRUGS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis
Ziniu Ding et al.
FRONTIERS IN IMMUNOLOGY (2021)
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo et al.
FRONTIERS IN ONCOLOGY (2021)
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis
J. I. Silverberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
Philipp K. Haber et al.
GASTROENTEROLOGY (2021)
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
Changhoon Yoo et al.
LIVER CANCER (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Review article: new therapeutic interventions for advanced hepatocellular carcinoma
Saroja Bangaru et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure
Khashayar Farsad et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks
Romina Brignardello-Petersen et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Combined locoregional-immunotherapy for liver cancer
Tim F. Greten et al.
JOURNAL OF HEPATOLOGY (2019)
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma
Jean-Louis Jouve et al.
JOURNAL OF HEPATOLOGY (2019)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma
Kai Wen Huang et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West
V. H. F. Lee et al.
CLINICAL ONCOLOGY (2019)
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Jens Ricke et al.
JOURNAL OF HEPATOLOGY (2019)
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
Ghassan K. Abou-Alfa et al.
JAMA ONCOLOGY (2019)
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
Joong-Won Park et al.
JOURNAL OF HEPATOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
Susan Feyerabend et al.
EUROPEAN JOURNAL OF CANCER (2018)
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
Dae-Won Lee et al.
BRITISH JOURNAL OF CANCER (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis
Hajime Aino et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Evaluation of inconsistency in networks of interventions
Areti Angeliki Veroniki et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
Georgia Salanti
RESEARCH SYNTHESIS METHODS (2012)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)